To hear about similar clinical trials, please enter your email below
Trial Title:
Toxoplasma Gondii Infection in Both Children and Adult Patients With Hematological Malignancies
NCT ID:
NCT05963295
Condition:
Toxoplasmosis
Conditions: Official terms:
Toxoplasmosis
Hematologic Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Screening
Masking:
None (Open Label)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
toxoplasma igG
Description:
Dignosis of toxoplasma
Arm group label:
control group
Arm group label:
patient with hematlolgical malignancies
Other name:
toxoplasma IgM
Summary:
Toxoplasmosis is one of the most common zoonotic diseases caused by the obligate
intracellular parasite, T. gondii. It affects up to one-third of the world's population
Horizontal transmission is mostly caused by ingestion of tissue cysts in infected meat,
or through consumption of food or drink contaminated with sporulated oocysts, while
vertical transmission occurs due to primary acquired maternal infection throughout
pregnancy.In immunocompetent hosts, acquired infection is asymptomatic in more than 80%
of cases, or is associated with fever,cervical lymphadenopathy, or myalgia.
In immunocompromised patients,toxoplasmosis is always life-threatening where toxoplasmic
encephalitis is the most important presentation. Among those patients, the disease may be
caused by a newly acquired infection, reactivation following cyst rupture, donation of a
cyst-containing organ from a seropositive donor to a seronegative recipient, or
reactivation of dormant infection in the recipient Patients with hematological malignancy
(HM), including those with acute myelogenous leukemia, and those who have undergone
hematopoietic stem cell transplantation or treated with aggressive immunosuppressive
regimens are at high risk of opportunistic infections The association between
toxoplasmosis and cancers remains dual. Most cancer patients are in a state of impaired
cellular and humoral immune systems either from the primary disease, or from chemotherapy
and/or radiotherapy administration. Chemotherapeutic drugs work by killing both fast
growing cancer cells, and healthy white blood cells causing neutropenia. So, patients
receiving chemotherapy are more susceptible to Toxoplasma infections.
Many studies have reported that the rate of reactivation of a latent T. gondii infection
was higher in different types of cancers particularly those of the eye, brain, blood and
breast. On the other side, T. gondii was also implicated as possible oncogenic pathogen
with suggested role in induction and progression of malignant diseases. This was
explained by many theories such as preventing apoptosis, enhancing the motility of
dendritic cells and macrophages.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- This study will be conducted on a group of patients who are diagnosed as have
hematological malignancies
Exclusion Criteria:
- Patients with other non hematological malignancies.
Gender:
All
Minimum age:
3 Years
Maximum age:
70 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Sohag university Hospital
Address:
City:
Sohag
Country:
Egypt
Contact:
Last name:
Magdy M Amin, professor
Start date:
August 2023
Completion date:
February 2025
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05963295
